Neuromyelitis optica
Drug research and approvals for neuromyelitis optica: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 47 studies of neuromyelitis optica are recruiting on ClinicalTrials.gov, Health Canada has authorized 11 drug trials for it since 2013, FDA has 4 approved and 4 open orphan designations naming it, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 47
- Trials authorized in Canada: 11
- FDA orphan approvals: 4
- EU medicines: 2
- A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSDNCT07762872 · Not reported · Junwei Hao, MD · starts Jul 20, 2026
- Safety and Efficacy Study of Sivelestat in Neuromyelitis Optica Spectrum DisorderNCT07738952 · Phase 1 / Phase 2 · Kyushu University · starts Oct 1, 2026
- Cohort Study on Neuroimmune Diseases in the Reproductive AgeNCT07653984 · Not reported · Third Affiliated Hospital, Sun Yat-Sen University · starts Apr 21, 2024
- Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With…NCT07557420 · Phase 3 · Alexion Pharmaceuticals, Inc. · starts Jul 20, 2026
- Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory…NCT07526493 · Phase 1 · Tongji Hospital · starts Apr 1, 2026
- Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum DisorderNCT07420296 · Phase 3 · Tianjin Medical University General Hospital · starts Jan 1, 2026
- Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World StudyNCT07410039 · Phase 4 · Chinese PLA General Hospital · starts Feb 1, 2026
- Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis…NCT07377305 · Not applicable · Tang-Du Hospital · starts Dec 8, 2025
- Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience…NCT07202494 · Not reported · Assistance Publique Hopitaux De Marseille · starts May 19, 2025
Approved 2
- SatralizumabIL6Ralpha/GP130 antagonist
- InebilizumabB-lymphocyte antigen CD19 binding agent
Phase 3 5
- EculizumabComplement C5 inhibitor
- AzathioprineAmidophosphoribosyltransferase inhibitor
- RavulizumabComplement C5 inhibitor
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- Divozilimab
Phase 2 12 of 14
- RituximabB-lymphocyte antigen CD20 binding agent
- CyclophosphamideDNA inhibitor
- TocilizumabInterleukin-6 receptor alpha subunit inhibitor
- Human immunoglobulin gReplacement therapy, immunomodulatory effects
- 2-mercaptoethanesulfonic acid
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- CytarabineDNA inhibitor
- MitoxantroneDNA topoisomerase II alpha inhibitor
- PrednisoneGlucocorticoid receptor agonist
- CarmustineGlutathione reductase inhibitor
- Bortezomib26S proteasome inhibitor
- DaratumumabLymphocyte differentiation antigen CD38 inhibitor
Phase 1 or earlier 9
- BaricitinibTyrosine-protein kinase JAK1 inhibitor
- OfatumumabB-lymphocyte antigen CD20 binding agent
- RuxolitinibTyrosine-protein kinase JAK1 inhibitor
- BevacizumabVascular endothelial growth factor A inhibitor
- CetirizineHistamine H1 receptor antagonist
- BelimumabTumor necrosis factor ligand superfamily member 13B inhibitor
- UblituximabB-lymphocyte antigen CD20 binding agent
- Human C1-esterase inhibitorPlasma kallikrein inhibitor
- BatoclimabIgG receptor FcRn large subunit p51 inhibitor
How its trials ended
133 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 22 whose ending is known, 45% met their primary endpoint, 5% missed it and 50% stopped early.
- Ongoing5844%
- Completed, result not reported3224%
- Status unknown2116%
- Met its primary endpoint108%
- Stopped: other or unclear75%
- Stopped: enrollment or feasibility43%
- Missed its primary endpoint11%
| Dec 7, 2022 | A phase I, multicenter, open-label, uncontrolled study to evaluate pharmacokinetics, pharmacodynamics, safety, and tolerability of satralizumab in adult…Enspryng | Roche | Closed |
| May 16, 2022 | A phase 2/3, open-label, historical-controlled, single-arm, multicenter smdy to evaluate the efficacy, pharmacokinetics, pharmacodynamics, and safety of…ALXN1210 | AstraZeneca Pharmaceuticals | Ongoing |
| May 9, 2022 | An open-label multicenter study to evaluate the pharmacokinetics, pharmacodynamics, and safety of inebilizumab in pediatric subjects with neuromyelitis optica…Inebilizumab (VIB0551) | Amgen | Pending |
| Nov 5, 2021 | Sakurabonsai: clinical, imaging and biomarker open-label study in neuromyelitis optica spectrum disorder (NMOSD) with satralizumab as an interventionSatralizumab (RO5333787) (SA237) | Roche | Ongoing |
| Nov 3, 2020 | A multicenter, single arm, open-label study to evaluate the long-term safety and efficacy of satralizumab in patients with neuromyelitis optica spectrum…Enspryng | Roche | Ongoing |
| Nov 13, 2019 | A phase 2/3 open-label, single-arm trial to evaluate the safety and activity of eculizumab in pediatric patients with relapsing neuromyelitis optica spectrum…Soliris | AstraZeneca Pharmaceuticals | Ongoing |
| Oct 29, 2019 | A phase 3, external placebo-controlled, open-label, multicenter study to evaluate the efficacy and safety of ravulizumab in adult patients with neuromyelitis…ALXN1210 | AstraZeneca Pharmaceuticals | Ongoing |
| Apr 11, 2014 | A multicenter, randomized, double-blind, placebo-controlled phase 3 study to evaluate the efficacy and safety, of SA237 as monotherapy in patients with…SA237 | Roche | Ongoing |
| Mar 20, 2014 | A double-masked, placebo-controlled study with open label period to evaluate the efficacy and safety of MEDI-551 in adult subjects with neuromyelitis optica…MEDI-551 | MedImmune LLC | Closed |
| Jun 27, 2013 | A phase III, open-label, extension trial of ECU-NMO-301 to evaluate the safety and efficacy of eculizumab in patients with relapsing neuromyelitis (NMO)Soliris | AstraZeneca Pharmaceuticals | Pending |
| Mar 22, 2024 | UltomirisTreatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive | Alexion Pharmaceuticals, Inc. | Approved |
| Aug 14, 2020 | EnspryngTreatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive | Genentech, Inc. | Approved |
| Jun 11, 2020 | UpliznaUplizna is indicated for for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4… | Horizon Therapeutics Ireland DAC | Approved |
| Jun 27, 2019 | SolirisSoliris is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4)… | Alexion Pharmaceuticals, Inc. | Approved |
| Feb 2, 2026 | RituximabTreatment of neuromyelitis optica spectrum disorder | Oddifact SAS | Designated |
| Apr 24, 2023 | EdralbrutinibTreatment of neuromyelitis optica spectrum disorder | eVenus Pharmaceutical Lab Inc. | Designated |
| Aug 25, 2016 | UblituximabTreatment of neuromyelitis optica and neuromyelitis optica spectrum disorder | TG Therapeutics, Inc. | Designated |
| Mar 19, 2015 | CladribineTreatment of neuromyelitis optica and neuromyelitis optica spectrum disorder | Chord Therapeutics S.a.r.l. | Designated |
| Apr 25, 2022 | UpliznaInebilizumab | Amgen Europe B.V. | EMA ↗ |
| Jun 24, 2021 | EnspryngSatralizumab · orphan | Roche Registration GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA